Provided by Tiger Trade Technology Pte. Ltd.

Beyondspring Inc

0.7700
-0.0033-0.43%
Post-market: 0.7672-0.0028-0.36%17:38 EDT
Volume:266.24K
Turnover:210.69K
Market Cap:31.66M
PE:-4.70
High:0.8498
Open:0.7000
Low:0.7000
Close:0.7733
52wk High:2.44
52wk Low:0.5657
Shares:41.12M
Float Shares:31.95M
Volume Ratio:0.12
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1638
EPS(LYR):-0.0249
ROE:-310.48%
ROA:-22.86%
PB:-0.89
PE(LYR):-30.93

Loading ...

BeyondSpring Says FDA Grants Fast Track Designation for Plinabulin-Docetaxel Phase 3 Dublin-4 NSCLC Trial

Reuters
·
Sep 29

BeyondSpring announces U.S. FDA granted Fast Track designation to Plinabulin

TIPRANKS
·
Sep 29

Beyondspring - Enters Open Market Sale Agreement with Citizens Jmp Securities on Sept 29, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 29

Beyondspring Inc: Entered into Open Market Sale Agreement Under Which Co May Offer and Sell up to 9.2 Mln Ordinary Shares

THOMSON REUTERS
·
Sep 29

BeyondSpring Sells Majority Stake in China Unit to Biolin to Fund Dublin-4 Trial Enrollment

Reuters
·
Sep 29

Beyondspring Announces FDA Fast Track Designation for Plinabulin in Post-Ici Non-Squamous Nsclc and Strategic Transaction to Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis

THOMSON REUTERS
·
Sep 29

Beyondspring - Sells Majority Equity Interest in Chinese Subsidiary to Fund Dublin-4 Trial in China

THOMSON REUTERS
·
Sep 29

Beyondspring - Retains Global Rights to Plinabulin Outside Greater China

THOMSON REUTERS
·
Sep 29

BeyondSpring Risks NASDAQ Delisting After Shares Trade Below $1 for 30 Days

Reuters
·
Sep 19

BeyondSpring Announces Annual Shareholder Meeting

Reuters
·
Sep 04

BeyondSpring Highlights Confirmatory Phase 3 Dublin-4 Trial Plan for Plinabulin in Post-ICI NSCLC

Reuters
·
Sep 01

BeyondSpring Posts Investor Deck Highlighting Plinabulin Late-Stage NSCLC Program and Immune-Modulating Approach

Reuters
·
Aug 16

BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoY

Benzinga Earnings
·
Aug 15

Beyondspring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 15

NASDAQ Trade Halt Volatility Trading Pause at 12:21 Pm

Reuters
·
Aug 14

Beyondspring Posts Corporate Presentation Spotlighting Plinabulin Immune-modulating Cancer Therapy Pipeline

Reuters
·
Jul 10

Beyondspring Files Form 3 for CFO Na Li Showing no Beneficial Ownership

Reuters
·
Jul 07

Beyondspring Amends Filing to Disclose CEO Min Qiu Pay Package, Including USD 100,000 Salary

Reuters
·
Jun 30

BeyondSpring names Min Qiu CEO in leadership transition effective July 1, 2026

Reuters
·
Jun 04

Beyondspring - Appoints Jiangwen (Jen) Majeti as Vice Chairman

THOMSON REUTERS
·
Jun 04